| __timestamp | Bio-Techne Corporation | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 60716000 | 72471000 |
| Thursday, January 1, 2015 | 119401000 | 89204000 |
| Friday, January 1, 2016 | 140879000 | 106010000 |
| Sunday, January 1, 2017 | 199243000 | 137905000 |
| Monday, January 1, 2018 | 240636000 | 159888000 |
| Tuesday, January 1, 2019 | 264359000 | 158425000 |
| Wednesday, January 1, 2020 | 260583000 | 200677000 |
| Friday, January 1, 2021 | 324951000 | 304759000 |
| Saturday, January 1, 2022 | 372766000 | 377221000 |
| Sunday, January 1, 2023 | 378378000 | 336361000 |
| Monday, January 1, 2024 | 396826000 |
Unleashing the power of data
In the ever-evolving biotech industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Bio-Techne Corporation and Supernus Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Bio-Techne's SG&A expenses surged by over 550%, peaking in 2024, while Supernus Pharmaceuticals saw a 360% increase, reaching its zenith in 2022.
Bio-Techne consistently outpaced Supernus in SG&A spending, reflecting its aggressive growth strategy. Notably, in 2022, Supernus briefly surpassed Bio-Techne, highlighting a strategic shift. However, by 2023, Bio-Techne regained its lead, underscoring its robust market position. The data for 2024 shows a gap for Supernus, indicating potential strategic realignments or reporting delays. This financial snapshot offers a window into the strategic priorities and market positioning of these biotech giants.
Who Optimizes SG&A Costs Better? Eli Lilly and Company or Bio-Techne Corporation
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Supernus Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. or Bio-Techne Corporation: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Bio-Techne Corporation vs Ascendis Pharma A/S
Cost Management Insights: SG&A Expenses for Bio-Techne Corporation and Pharming Group N.V.
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or Supernus Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Corcept Therapeutics Incorporated and Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? TG Therapeutics, Inc. or Supernus Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: CymaBay Therapeutics, Inc. vs Supernus Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Viking Therapeutics, Inc. and Supernus Pharmaceuticals, Inc.
Ligand Pharmaceuticals Incorporated and Supernus Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Supernus Pharmaceuticals, Inc. vs Galapagos NV Trends and Insights